Founded in 1963 in Hamburg by the company’s namesake Alfred E. Tiefenbacher as the world’s first exclusive active pharmaceuticals ingredient – API agency, AET has been growing successfully in the market for active pharmaceuticals for 50 years. Representing API producers has provided the foundation for AET’s growth into a pharmaceutical company capable of independently developing, registering and supplying finished dosage form (FDF) generic pharmaceuticals to marketing organisations internationally. AET enjoys an industry leading reputation for technical excellence and service. AET has continuously anticipated the significant developments and changes of the pharmaceutical market, and has also evolved into a worldwide valued partner for industry in the fast growing generics market.
Alfred E. Tiefenbacher founded AET in 1963 following 20 years of working in the pharmaceutical industry and serving on the board of Boehringer Ingelheim.
His idea, the procurement of APIs for commissioners from the pharmaceutical industry still forms the core competence of AET even today.
The founding in 2003 of a galenic development site, AET Labs in Hyderabad, India, was a further milestone on AET’s successful path towards a backwardly integrated corporation. At the Hyderabad site, highly motivated scientists and technicians develop and document generics through to validated approval and market launch.
Today, the AET team comprises more than 400 international specialists located in the German HQ, India, Cyprus, Malta and China.
We at AET are driven by our mission to makepharmaceutical productsof thehighestquality affordablefor everybody.
We are afamily ownedbusiness and believe inentrepreneurshipandflat hierarchies. That enables us to act quickly on theneeds of our global clientsas well as to changing market conditions.